Skip to main content
Medivir logo

Medivir — Investor Relations & Filings

Ticker · MVIR ISIN · SE0020181014 LEI · 549300VWDGUX0WMJ1T79 ST Manufacturing
Open in API
Filings indexed 965 across all filing types
Latest filing 2014-04-30 Regulatory Filings
Country SE Sweden
Listing ST MVIR

About Medivir

https://www.medivir.com/

Medivir is a pharmaceutical company specializing in the discovery and clinical development of innovative drugs for cancer. The company focuses on oncology areas with high unmet medical needs, aiming to provide transformative treatments for patients with limited therapeutic options. Its research and development strategy is based on extensive expertise in drug design, particularly targeting enzymes such as proteases and polymerases, and includes the use of a proprietary prodrug platform. Medivir actively pursues collaborations with academic and industrial partners to advance its pipeline from research through to commercialization.

Recent filings

Filing Released Lang Actions
Adasuve will now be launched in Sweden, Norway, Finland and Denmark
Regulatory Filings Classification · 95% confidence The document is a press release from Medivir AB announcing the launch of their product Adasuve in Sweden, Norway, Finland, and Denmark, following a license agreement with Ferrer. It details the product, the market need (agitation treatment), and provides background information on the involved companies (Medivir, Ferrer, Alexza). This type of announcement, focusing on commercial activity, product updates, and market expansion, is characteristic of a general corporate announcement or press release. Since it is not a formal regulatory filing like a 10-K, a specific financial report (IR, MRQ), or a management/board change, it fits best under the general 'Regulatory Filings' (RNS) category as a broad corporate communication, or potentially an Earnings Release (ER) if it were tied to a specific reporting period, but here it is purely commercial news. Given the options, RNS serves as the best general corporate announcement fallback.
2014-04-30 English
Adasuve lanseras nu i Sverige, Norge, Finland och Danmark
Regulatory Filings Classification · 95% confidence The document announces the launch of a product, Adasuve, in several Nordic countries by Medivir AB. It details the product, its indication (agitation in schizophrenia/bipolar disorder), the partnership with Ferrer, and provides background information on the condition and the companies involved. This type of announcement, focusing on a specific commercial event (product launch/availability) and providing context, is characteristic of a general press release or regulatory announcement. Since it is not a full financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a specific shareholder/insider filing, the most appropriate general category for a corporate news announcement that doesn't fit elsewhere is 'Regulatory Filings' (RNS), which often serves as a catch-all for press releases filed with exchanges, or potentially an 'Earnings Release' (ER) if it were tied to a reporting period, but here it is a product commercialization update. Given the nature of the announcement (product launch/commercial update) and the lack of specific financial reporting structure, RNS is the best fit as a general regulatory announcement/press release.
2014-04-30 Swedish
Positivt marknadsmottagande för Simeprevir under första kvartalet 2014
Earnings Release Classification · 98% confidence The document is a press release from Medivir AB announcing positive market reception and strong sales figures for Simeprevir during the first quarter of 2014, specifically mentioning sales figures ($354 MUSD) and royalty income (162 MSEK). It also announces a short conference call regarding these figures. Crucially, it states: "Medivir kommer att publicera sitt fullständiga bokslut för första kvartalet 2014 den 8 maj." (Medivir will publish its full first-quarter 2014 financial report on May 8th). Since this document primarily releases key financial highlights (sales figures) and announces a future, more comprehensive report, it fits the definition of an Earnings Release (ER). It is not the full report (IR) nor is it the transcript of the call (CT). Given the short length (3624 chars) and the announcement of a future full report, it is clearly an initial results announcement. Q1 2014
2014-04-15 Swedish
Good market uptake for Simeprevir during the first quarter 2014
Earnings Release Classification · 98% confidence The document is a press release from Medivir AB announcing strong sales uptake for its drug simeprevir during the first quarter of 2014 and providing specific royalty figures. Crucially, it states, "Medivir will publish its first quarter report on May 8, 2014," and it also announces a conference call. This structure—announcing results highlights and referencing a future, more comprehensive report—is characteristic of an Earnings Release (ER). It is not the full report (IR or 10-K), nor is it just a notice about the report's publication (RPA). It contains the key financial highlights (sales figures and royalties) for the period. Q1 2014
2014-04-15 English
Final data from the phase II COSMOS study with Simeprevir in combination with Sofosbuvir presented at EASL
Regulatory Filings Classification · 98% confidence The document is a press release from Medivir AB announcing positive final data from a Phase II clinical study (COSMOS) involving their drug Simeprevir, presented at an industry conference (EASL 2014). It details efficacy results (SVR12 rates) across various patient subgroups and treatment regimens. This type of announcement, focusing on clinical trial results and scientific presentations, is characteristic of an Earnings Release (ER) or a general press release related to business operations and pipeline updates. Since it is a specific announcement of results rather than a comprehensive quarterly/annual report (10-K or IR), and it is not a transcript (CT) or a formal investor presentation (IP), the most fitting category is Earnings Release (ER), as these often include pipeline updates alongside financial highlights, or Regulatory Filing (RNS) if it were purely regulatory. Given the content is a detailed scientific update presented at a conference, it functions as a key business update, aligning best with ER, which covers periodical financial/operational highlights. However, since it is not explicitly labeled as an 'Earnings Release' and focuses heavily on clinical data presentation, it could also be considered a general Regulatory Filing (RNS) or an Investor Presentation (IP) if it were a slide deck. Since it is a press release format detailing study results, ER is the closest fit for a significant operational update, though RNS is a strong fallback. Given the context of reporting clinical trial progress, which is a major operational highlight, I will classify it as ER, as these releases often precede or accompany formal financial reporting periods.
2014-04-12 English
Finala data från fas II-studien COSMOS med Simeprevir i kombination med Sofosbuvir har presenterats vid EASL
Regulatory Filings Classification · 92% confidence The document is a press release from Medivir AB announcing the presentation of final Phase II study data (COSMOS study) and Phase III data (RESTORE, QUEST, PROMISE studies) regarding their drug Simeprevir at the EASL conference. It details clinical trial results (SVR12 rates, adverse events) and concludes with contact information and a statement about public disclosure requirements ('Informationen lämnades för offentliggörande den 12 april 2014'). This format—a formal announcement of recent scientific/clinical progress, often released to the public market, but not a full financial report (10-K, IR) or a transcript (CT)—best fits the category for an initial announcement of results or significant operational updates. Since it is a detailed announcement of clinical trial results rather than just key financial highlights, it is more specific than a general Regulatory Filing (RNS). However, it is not a comprehensive Interim Report (IR) or Annual Report (10-K). Given the content focuses on clinical trial outcomes and regulatory progress (EMA submission updates), it functions as a significant operational update. In the provided definitions, this type of announcement, which details scientific progress and is released via press wire, often falls under a general regulatory announcement or an Investor Presentation if it were a slide deck. Since it is a press release detailing study results, and not a formal financial report, the most appropriate classification among the choices is either 'ER' (if interpreted as an 'earnings' equivalent for clinical milestones) or 'RNS' (as a general regulatory announcement). Given the focus is purely scientific/clinical data presentation, and not financial performance highlights, 'RNS' (Regulatory Filings / General regulatory announcements) serves as the best fit for a non-financial, non-presentation, non-transcript announcement of material information.
2014-04-12 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.